Topics Administrative Hearings DEA Proposes Significant Changes to Administrative HearingsDoes the New Rule on Interlocutory Appeals Undermine the Independence of DEA’s ALJs? Conferences Annual ASPL Pharmacy Law Seminar is Back and In PersonIn Pharmaceutical Distribution? Join Me Virtually at the Distribution Management ConferenceASPL Virtual Conference: Your Rx for Developments in Pharmacy Law Controlled Substance Solutions Introducing ARCOS IQ Corresponding Responsibility I Always Feel Like Somebody’s Watching MeIgnore Red Flags at Your Own PerilLawsuits Filed Against Retail Chain Pharmacies: The Corresponding Responsibility Catch-22 COVID-19 OMB Has a Backlog of DEA Regulatory ActionsDEA: COVID-19 Does Not Relieve Distributors of Certain Compliance ObligationsDEA Announces Exception to 5% Rule DEA Compliance Introducing ARCOS IQI Always Feel Like Somebody’s Watching MeIgnore Red Flags at Your Own Peril DEA Final Orders Review of Administrative Actions Ignore Red Flags at Your Own PerilDEA’s New/Old View on Due Diligence RequirementsDEA Proposes Significant Changes to Administrative Hearings Drug Policy A Distributor’s Conundrum: When DEA and state law collideCongress Seeks to Provide Clarity on Suspicious Order MonitoringDEA Issues New/Old Guidance on Suspicious Order Monitoring Due Diligence Introducing ARCOS IQI Always Feel Like Somebody’s Watching MeNew Software Platform for Controlled Substance Compliance Enforcement Actions Ignore Red Flags at Your Own PerilActive Prosecution Continues for Controlled Substance ViolationsDEA’s New/Old View on Due Diligence Requirements Legislation A Distributor’s Conundrum: When DEA and state law collideCongress Seeks to Provide Clarity on Suspicious Order MonitoringDEA Establishes Registration Category for EMS Agencies Overdose FDA Approves New Packaging for “Poor Man's Methadone”DEA Decisions: In the Matter of Wesley Pope, M.D.Surgeon General Seeks Support from Doctors to End Opioid Epidemic Quota DEA Submits Proposed Quotas for 2021DEA Proposes Decreasing Opioid Quotas for 2020DEA to Propose Significant Regulatory Changes in the Coming Year Scheduling Actions Alabama Battle Over Alprazolam is Done. For Now.Alabama Continues Efforts to Make Alprazolam a Schedule II DrugAlprazolam a Schedule II Substance? State Law A Distributor’s Conundrum: When DEA and state law collideLawsuits Filed Against Retail Chain Pharmacies: The Corresponding Responsibility Catch-22The Curious Case of Colorado: DEA Sues the BOP Subpoenas, Warrants, Inspections DEA Must Obtain a Warrant to Access PDMP Data in Oregon Suspicious Order Monitoring Congress Seeks to Provide Clarity on Suspicious Order MonitoringDEA Issues New/Old Guidance on Suspicious Order MonitoringDEA Creates Two-Option Framework for Reporting Suspicious Orders Suspicious Order Reports DEA Creates Two-Option Framework for Reporting Suspicious OrdersDEA: COVID-19 Does Not Relieve Distributors of Certain Compliance ObligationsDEA Poised to Roll Out Three Regulations in the Coming Months Uncategorized Breaking News: DEA Provides Additional Access to ARCOS Data
